Fresenius SE & Co. KGaA has signed a strategic development agreement with TQ Therapeutics to advance scalable and efficient manufacturing of cell and gene therapies. Under the agreement, Fresenius Kabi, an operating company of Fresenius, obtains an exclusive license to integrate TQ Therapeutics' proprietary cell selection technology into the Cue® Cell Processing System. The combined solution enables the isolation of highly pure T-cells in under two hours, aiming to streamline processes and accelerate the development of new therapies. This collaboration aligns with Fresenius's strategy to focus on high-quality healthcare platforms and improve patient access through operational excellence and innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.